Recombinant III-type humanized collagen, nucleotide sequence, preparation method and application

Through the recombinant type III humanized collagen produced in bacteria, yeast or plant expression systems, the problems of allergies and low biological activity caused by animal-derived collagen are solved, and the low toxicity and high biological activity of collagen are achieved, suitable for A variety of medical and cosmetic fields.

CN118994367APending Publication Date: 2024-11-22GECOLL BIOMEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310568138.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing collagen products from animal tissues may cause allergic reactions, the biological activity produced through the prokaryotic expression system is low and the purification is difficult, and the molecular weight is large and difficult to absorb by the human body.

Method used

Develop recombinant type III humanized collagen, produced by bacteria, yeast or plant expression systems. The preparation method includes constructing expression vectors and expressing and purifying the product. The product has a small molecular weight and high water solubility, is easy to absorb, and is used in biomedical materials. , beauty care products and food additives.

Benefits of technology

It achieves low toxicity, easy absorption and high biological activity of collagen, improves skin moisturizing and keratinocyte function, and is suitable for a variety of medical and cosmetic fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994367A_ABST
    Figure CN118994367A_ABST
Patent Text Reader

Abstract

The invention provides recombinant III-type humanized collagen as well as a nucleotide sequence, a preparation method and application thereof. The recombinant III-type humanized collagen comprises an amino acid sequence which has the similarity of 70% or more with SEQ ID NO: 6 or a nucleotide sequence which has the similarity of 90% or more with SEQ ID NO: 7. The preparation method of the recombinant III-type humanized collagen comprises the following steps: constructing an expression vector comprising the nucleotide sequence; and transforming the expression vector into a bacterial cell, a yeast cell or a plant callus cell for expression so as to generate the recombinant III-type humanized collagen. The recombinant human collagen can be used in biomedical materials, artificial cell culture, cosmetics, cosmetic care products, food additives and cosmetic medical products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to human collagen, in particular to a recombinant type III humanized collagen and its nucleotide sequence, preparation method and use. Background Art

[0002] Collagen accounts for about 20% to 30% of the total protein in the animal body. It is a structural protein in the extracellular space and is also the main component of connective tissue. It exists in tendons, ligaments, skin, cornea and other tissues.

[0003] There are five main types of collagen. Type I collagen is mainly found in skin, tendons, organs and bones; type II collagen is mainly found in cartilage; type III collagen is the main component of reticulin; type IV collagen mainly constitutes basal laminin and is found in the basement membrane of epithelial tissue; type V collagen is found on the cell surface, in hair or in the placenta.

[0004] Collagen has extremely high economic value and can be widely used for medical and cosmetic purposes. For example, it can be used as a supporting material for stem cell culture systems to assist stem cell growth, a material for coating drugs on drug-containing cardiovascular stents, a dressing for wounds of patients with burns and scalds, collagen hemostatic pads, collagen membrane bone fillers, moisturizing anti-aging cosmetics, oral nutritional supplements, etc. Most of the collagen products currently on the market use type I collagen.

[0005] The collagen added to the products currently on the market is mainly extracted from animal tissues or obtained through genetic engineering methods. However, collagen extracted from animal tissues may cause allergic reactions. The use of prokaryotic expression systems to produce collagen has low biological activity due to the problem of imperfect post-translational processing and modification. In addition, collagen is usually expressed in the form of inclusion bodies, which makes purification difficult. The use of animal cell expression systems to produce collagen may lead to concerns about viral contamination of the produced collagen.

[0006] In addition, since the molecular weight of collagen is hundreds of thousands of Daltons, if collagen is not hydrolyzed into smaller molecules, it will be difficult to be absorbed by the human body.

[0007] Therefore, developing collagen with a smaller size and a preparation method thereof to facilitate human absorption and apply it to the medical and beauty fields is a problem to be solved in the art. Summary of the invention

[0008] The present disclosure provides a recombinant type III humanized collagen protein, wherein the recombinant type III humanized collagen protein comprises an amino acid sequence having a similarity of more than 70% to SEQ ID NO:6.

[0009] In a specific embodiment, the recombinant humanized type III collagen comprises an amino acid sequence having 70%, 75%, 80%, 85% or 90% similarity to SEQ ID NO:6.

[0010] In one specific embodiment, the recombinant humanized type III collagen comprises an amino acid sequence having 92% similarity to SEQ ID NO: 6. In another specific embodiment, the recombinant humanized type III collagen comprises an amino acid sequence having 95% similarity to SEQ ID NO: 6. In another specific embodiment, the recombinant humanized type III collagen comprises an amino acid sequence having 98% similarity to SEQ ID NO: 6.

[0011] The present disclosure further provides a nucleotide sequence encoding the recombinant humanized type III collagen, wherein the nucleotide sequence comprises a sequence having a similarity of more than 90% to SEQ ID NO:7.

[0012] In a specific embodiment, the nucleotide sequence encoding the recombinant humanized type III collagen comprises a sequence having 90%, 92%, 94%, 96% or 98% similarity to SEQ ID NO:7.

[0013] The present disclosure further provides a method for preparing the recombinant humanized type III collagen, the method comprising the steps of:

[0014] Constructing an expression vector comprising a nucleotide sequence encoding the recombinant humanized type III collagen; and

[0015] The expression vector is transformed into bacterial cells, yeast cells or plant cells for expression to produce the recombinant humanized type III collagen.

[0016] In a specific embodiment, the method further comprises the step of purifying the recombinant humanized type III collagen from the bacterial cell, the yeast cell or the plant cell after transforming the expression vector into the bacterial cell, the yeast cell or the plant cell for expression.

[0017] In a specific embodiment, the plant cell is a protoplast or a cell from a plant callus or leaf.

[0018] In a specific embodiment, the step of transforming the expression vector into the plant cell for expression is performed using a plant transient expression system or a plant stable expression system.

[0019] The present disclosure further provides a use of the recombinant humanized type III collagen, wherein the recombinant humanized type III collagen is used in biomedical materials, artificial cell culture, cosmetics, beauty care products, food additives and cosmetic medicine products.

[0020] In a specific embodiment, the biomedical materials include collagen hemostatic cotton, surgical sutures, wound dressings, bone fillers, artificial blood vessels and soft tissue fillers.

[0021] In a specific embodiment, the cosmetics and skin care products include collagen moisturizing lotion, collagen cream and collagen facial mask.

[0022] In a specific embodiment, the food additive is added to bone and joint health food or anti-aging health food.

[0023] In a specific embodiment, the cosmetic medicine product comprises a cosmetic medicine injection.

[0024] Compared to natural human type III collagen, the recombinant type III humanized collagen disclosed herein has a smaller size of about 65 kDa, has good water solubility, and is easily absorbed by the human body or skin. In addition, the recombinant type III humanized collagen disclosed herein can be produced by a bacterial expression system, a yeast expression system, or a plant expression system. Since the recombinant type III humanized collagen has a smaller molecular weight than natural human type III collagen, the produced recombinant type III humanized collagen can be used without undergoing an acid treatment procedure. Furthermore, the recombinant humanized type III collagen disclosed in the present invention is non-toxic to human skin keratinocytes (HaCaT), and can increase the expression levels of human hyaluronan synthase 2 (hHAS-2), human hyaluronan synthase 3 (hHAS-3), human loricrin (hLOR) and human filaggrin (hFLG) in human skin keratinocytes, thereby achieving the effect of improving skin moisturizing and strengthening keratinocytes. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0026] Figure 1This is a graph showing the result of multiple sequence alignment using MEGA software of the amino acid sequence of COL3A1 as shown in SEQ ID NO: 1, the amino acid sequence of COL1A1 as shown in SEQ ID NO: 2, the amino acid sequence of COL1A2 as shown in SEQ ID NO: 3, the amino acid sequence of COL2A1 as shown in SEQ ID NO: 4, and the amino acid sequence of COL5A1 as shown in SEQ ID NO: 5.

[0027] Figure 2 The figure is the result of detecting recombinant humanized type III collagen (GEcol3a) by western blotting, wherein M is the molecular weight marker of the protein; lane 1 is the protein of wild-type rice suspension cells; lane 2 is the protein of transfected rice suspension cells; and lane 3 is the purified recombinant humanized type III collagen.

[0028] Figure 3 The graph shows the toxicity of proteins from wild-type rice suspension cells and proteins from transfected rice suspension cells to human skin keratinocytes (HaCaT).

[0029] Figure 4 The graph shows the expression levels of human hyaluronan synthase 2 (hHAS-2), human loricrin (hLOR) and human filaggrin (hFLG) in human skin keratinocytes after the human skin keratinocytes were treated with 50 μg / mL of wild-type rice suspension cell protein or 50 μg / mL of transgenic rice suspension cell protein.

[0030] Figure 5 This graph shows the expression levels of human hyaluronan synthase 2, human hyaluronan synthase 3 and human filaggrin in human skin keratinocytes after the human skin keratinocytes were treated with 75 μg / mL of wild-type rice suspension cell protein or 50 μg / mL of transgenic rice suspension cell protein. DETAILED DESCRIPTION

[0031] The following specific embodiments are used to illustrate the disclosure of the present invention. After reading the disclosure of this specification, those skilled in the art can easily understand its advantages and effects.

[0032] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural individuals unless the context dictates otherwise.

[0033] Unless otherwise indicated herein, the term "or" used in the specification and the appended claims includes the meaning of "and / or".

[0034] Unless otherwise specified herein, the "stable plant expression system" used in the specification and the appended patent claims refers to the integration of foreign genes into the genome of the plant.

[0035] The present disclosure explains details through examples of embodiments, but the interpretation of the present disclosure should not be limited to the description of the following embodiments.

[0036] Preparation Example 1: Construction of pENTR (GEcol3a) plasmid

[0037] Design of recombinant humanized type III collagen:

[0038] The BlastP program in the BLAST (Basic Local Alignment Search Tool) of the National Center for Biotechnology Information (NCBI) website (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) was used to align the partial type III collagen (COL3A1, GenBank Accession No.: AAL13167.1) sequence as shown in SEQ ID NO: 1 with the amino acid sequence in the protein database, and the type I collagen (COL1A1, GenBank Accession No.: AAH36531.1) as shown in SEQ ID NO: 2 with a 60% similarity to the amino acid sequence of SEQ ID NO: 1, the type I collagen (COL1A2, GenBank Accession No.: AAH42586.1) as shown in SEQ ID NO: 3 with a 56% similarity, and the type I collagen (COL1A3, GenBank Accession No.: AAH42586.1) as shown in SEQ ID NO: 4 with a 64% similarity to the amino acid sequence of SEQ ID NO: 1 were selected. The type II collagen (COL2A1, GenBank Accession No.: XP_016874317.1) shown in SEQ ID NO: 4, and the type V collagen (COL5A1, GenBank Accession No.: AAH86874.1) shown in SEQ ID NO: 5 having a similarity of 56%.

[0039] See also Figure 1, using MEGA software, a multiple sequence alignment was performed between the amino acid sequence of COL3A1 as shown in SEQ ID NO: 1, the amino acid sequence of COL1A1 as shown in SEQ ID NO: 2, the amino acid sequence of COL1A2 as shown in SEQ ID NO: 3, the amino acid sequence of COL2A1 as shown in SEQ ID NO: 4, and the amino acid sequence of COL5A1 as shown in SEQ ID NO: 5, and the non-conserved region (non-conserved region) and the amino acid sequence of Gly-XY repeats that can form a triple helix (such as the sequence marked by the square bar) between the amino acid sequence of COL3A1 as shown in SEQ ID NO: 1 and the amino acid sequences as shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 were found. The segments of the amino acid sequence of COL3A1 as shown in SEQ ID NO: 1 indicated by the square bars were combined to obtain the amino acid sequence of the recombinant type III humanized collagen (GEcol3a) as shown in SEQ ID NO: 6, which has 41.8% identity with the amino acid sequence of type XXIV collagen (COL24A1, GenBank Accession No.: AAI13655.1) and 34.7% identity with the amino acid sequence of type III collagen (COL3A1, GenBank Accession No.: AAL13167.1).

[0040] The DNA sequence of GEcol3a as shown in SEQ ID NO: 7 was synthesized by gene synthesis, and restriction enzyme sequences HindIII and EcoRI were added to the 5' and 3' ends of the GEcol3a DNA sequence, respectively. The GEcol3a DNA sequence was then ligated into the pENTR(MCS) plasmid using T4 DNA ligase and transformed into Escherichia coli DH5α competent cells. Finally, Escherichia coli containing the pENTR(GEcol3a) plasmid were selected using kanamycin to obtain the pENTR(GEcol3a) plasmid.

[0041] Preparation Example 2: Construction of pZP200 (35S: GEcol3a) plasmid

[0042] The GEcol3a DNA in the pENTR(GEcol3a) plasmid was transferred to the pZP200(35S:attR-NOS) plasmid using the Gateway LR cloning method (Invitrogen) and transformed into Escherichia coli DH5α competent cells. The Escherichia coli containing the pZP200(35S:GEcol3a) plasmid was then selected using spectinomycin to obtain the pZP200(35S:GEcol3a) plasmid.

[0043] Preparation Example 3: Transformation of Rice Callus

[0044] The pZP200(35S:GEcol3a) plasmid was transformed into EHA105 Agrobacterium competent cells by electroporation, and then selected by spectinomycin to obtain Agrobacterium containing pZP200(35S:GEcol3a).

[0045] The dehulled seeds of wild-type Zhonghua 11 (ZH11) rice were soaked in 75% alcohol for 1 minute, washed twice with reverse osmosis water to remove the residual alcohol, and then placed in 3% bleach water with a final concentration of 0.1% Tween 20, sterilized by ultrasound for 20 minutes, and then rinsed with sterile water to obtain sterilized seeds. The sterilized seeds were placed on MS (pH 5.7) medium containing 2ppm 2,4-dichlorophenoxyacetic acid (2,4-D) to obtain callus tissue.

[0046] After subculture, the callus was placed on MS medium containing 100 μM acetosyringone and 2 ppm 2,4-D and cultured at 28°C for 3 days. Agrobacterium containing pZP200 (35S: GEcol3a) was cultured in LB medium containing 30 μM acetosyringone overnight, and then the Agrobacterium was obtained by centrifugation at 5000xg and suspended in MS medium containing 100 μM acetosyringone. Then, the rice callus that had been cultured for three days was poured into the culture medium. After infection for 15 to 20 minutes, the bacterial solution was aspirated as much as possible, and then the rice callus was cultured at 25°C in the dark for 2 to 3 days for co-infection.

[0047] The infected callus tissue was washed and placed on MS medium containing 2 ppm 2,4-D, 50 ppm hygromycin and 150 ppm Timentin, and cultured at 28° C. in the dark. The callus tissue was then placed in MS culture medium for suspension culture to obtain transfected rice suspension cells.

[0048] Preparation Example 4: Extraction of Protein from Wild-Type Rice Suspension Cells

[0049] Wild-type rice suspension cells were placed in a mortar and ground into powder in liquid nitrogen to obtain wild-type rice suspension cell powder. Proteins in the wild-type rice suspension cells were extracted using an extracting solution (25 mM Tris-HCl, 300 mM NaCl, pH 8.0) with a volume 2.5 times the weight of the wild-type rice suspension cell powder to obtain proteins in the wild-type rice suspension cells, and then the protein concentration of the wild-type rice suspension cells was detected using a BCA (bicinchoninic acid) protein quantification kit.

[0050] Example 1: Detection of recombinant humanized type III collagen (GEcol3a) produced in transfected rice suspension cells using Western blotting

[0051] The transfected rice suspension cells were placed in a mortar and ground into powder in liquid nitrogen to obtain transfected rice suspension cell powder. Proteins in the rice suspension cells were extracted using an extracting solution (25 mM Tris-HCl, 300 mM NaCl, pH 8.0) with a volume 2.5 times the weight of the transfected rice suspension cell powder to obtain proteins in the transfected rice suspension cells, and then the protein concentration of the transfected rice suspension cells was detected using a BCA protein quantification kit.

[0052] Recombinant humanized type III collagen (GEcol3a) was purified from proteins of transfected rice suspension cells using a His-tag protein purification (Ni-NTA column method) kit to obtain purified recombinant humanized type III collagen (GEcol3a).

[0053] 100 μg of protein from wild-type rice suspension cells, 100 μg of transfected rice suspension cells, and 20 μg of purified recombinant humanized type III collagen (GEcol3a) were injected into the lanes of 8% SDS polyacrylamide gel electrophoresis, and electrophoresis was performed at a fixed current of 30 mA for 90 minutes. The proteins on the electrophoresis gel were transferred to a polyvinylidene fluoride (PVDF) membrane using the wet blotting method, and then western blotting was performed using rabbit anti-HA antibody and rabbit anti-IgG antibody.

[0054] See also Figure 2The Western blotting results showed that both Lane 2 (transformed rice suspension cells) and Lane 3 (purified recombinant type III humanized collagen) (GEcol3a) showed recombinant type III humanized collagen (GEcol3a) of the expected size of 70 kDa. It can be seen that the recombinant type III humanized collagen (GEcol3a) as shown in SEQ ID NO: 6 has been successfully expressed in the transfected rice suspension cells.

[0055] Example 2: Testing the toxicity of transfected rice suspension cells to human skin keratinocytes (HaCaT)

[0056] HaCaT keratinocytes were seeded in a 96-well plate containing cell culture medium, and each well contained 1x10 4 After culturing for 24 hours, the 96-well plate was placed in a cell culture incubator, the culture medium was removed, and 100 μl of 0 μg / mL, 25 μg / mL, 50 μg / mL, 75 μg / mL and 100 μg / mL wild-type rice suspension cell protein or transfected rice suspension cell protein was added to each well, respectively. After culturing for 24 hours, the culture medium was removed again, 10% CCK8 reagent was added to each well, and the detection was performed at a wavelength of 450 nm after culturing for 2 hours.

[0057] See also Figure 3 The results showed that the proteins from wild-type rice suspension cells and the proteins from transfected rice suspension cells were not toxic to HaCaT keratinocytes.

[0058] Example 3: The expression levels of human hyaluronan synthase 2 (hHAS-2), human hyaluronan synthase 3 (hHAS-3), human loricrin (hLOR) and human filaggrin (hFLG) in human skin keratinocytes (HaCaT) were detected by transfected rice suspension cells.

[0059] HaCaT cells were seeded in a 6 cm cell culture dish containing cell culture medium, and each well contained 5x10 5After culturing for 24 hours, a 6-cm cell culture dish was placed in a cell culture incubator, the culture medium was removed, and 5 ml of 50 μg / mL and 75 mg / mL wild-type rice suspension cell protein or transfected rice suspension cell protein was added to each well, respectively. After culturing for 24 hours, each cell was washed with 1X phosphate-buffered saline (PBS), and RNA of each cell was extracted.

[0060] By quantitative real-time PCR (q-PCR), the expression level of human hyaluronan synthase 2 (hHAS-2) was detected using the forward primer shown in SEQ ID NO: 8 and the reverse primer shown in SEQ ID NO: 9; the expression level of human hyaluronan synthase 3 (hHAS-3) was detected using the forward primer shown in SEQ ID NO: 10 and the reverse primer shown in SEQ ID NO: 11; the expression level of human loricrin (hLOR) was detected using the forward primer shown in SEQ ID NO: 12 and the reverse primer shown in SEQ ID NO: 13; and the expression level of human filaggrin (hFLG) was detected using the forward primer shown in SEQ ID NO: 14 and the reverse primer shown in SEQ ID NO: 15.

[0061] See also Figure 4 and Figure 5 The results showed that compared with human skin keratinocytes treated with 50μg / mL and 75mg / mL of wild-type rice suspension cell protein, human skin keratinocytes treated with 50μg / mL and 75mg / mL of transgenic rice suspension cell protein significantly increased the expression of human hyaluronan synthase 2 (hHAS-2), human hyaluronan synthase 3 (hHAS-3), human loricrin (hLOR) and human filaggrin (hFLG) by 15.6%, 12.6%, 10.9% and 16.3%, respectively. It can be seen that the protein of transgenic rice suspension cells can promote the expression of human hyaluronan synthase 2 (hHAS-2), human hyaluronan synthase 3 (hHAS-3), human loricrin (hLOR) and human filaggrin (hFLG) in human skin keratinocytes.

[0062] As can be seen from the above, the recombinant type III humanized collagen disclosed in the present invention has a relatively small size of about 65kDa, has good water solubility, and is easily absorbed by the human body or skin. In addition, the recombinant type III humanized collagen can be obtained by a rice callus expression system, and because the recombinant type III humanized collagen has a smaller molecular weight than natural human type III collagen, the recombinant type III humanized collagen can be used without the need for an acid treatment procedure. Furthermore, the recombinant type III humanized collagen is non-toxic to HaCaT keratinocytes, and can increase the expression of human hyaluronan synthase 2 (hHAS-2), human hyaluronan synthase 3 (hHAS-3), human loricrin (hLOR) and human silk polymerase hFLG) in human skin keratinocytes, thereby achieving the effect of improving skin moisturizing and strengthening keratinocytes.

[0063] The above embodiments are used to illustrate the principles and effects of the present disclosure, but are not used to limit the present disclosure. Any person skilled in the art may modify the above embodiments without violating the spirit and scope of the present disclosure. Therefore, the scope of protection of the present disclosure should be as listed in the claims.

Claims

1. A recombinant humanized type III collagen, characterized in that: The recombinant type III humanized collagen comprises an amino acid sequence having a similarity of more than 70% to SEQ ID NO:

6.

2. The recombinant humanized type III collagen according to claim 1, characterized in that: The recombinant type III humanized collagen comprises an amino acid sequence having a similarity of more than 80% to SEQ ID NO:

6.

3. A nucleotide sequence encoding the recombinant humanized type III collagen according to claim 1 or 2, characterized in that: The nucleotide sequence includes a sequence having a similarity of more than 90% to SEQ ID NO:

7.

4. A method for preparing the recombinant humanized type III collagen as claimed in claim 1 or 2, characterized in that: The method comprises the steps of: constructing an expression vector comprising the nucleotide sequence of claim 3; and The expression vector is transformed into bacterial cells, yeast cells or plant cells for expression to produce the recombinant humanized type III collagen, wherein the plant cells are protoplasts or cells from plant callus or leaves.

5. The method according to claim 4, characterized in that: The method further comprises the step of purifying the recombinant humanized type III collagen from the bacterial cell, the yeast cell or the plant cell after the step of transforming the expression vector into the bacterial cell, the yeast cell or the plant cell for expression.

6. A use of the recombinant humanized type III collagen as claimed in claim 1 or 2, characterized in that: The recombinant type III humanized collagen is used in biomedical materials, artificial cell culture, cosmetics, beauty care products, food additives and cosmetic medicine products.

7. The use according to claim 6, characterized in that: The biomedical materials include collagen hemostatic cotton, surgical sutures, wound dressings, bone fillers, artificial blood vessels and soft tissue fillers.

8. The use according to claim 6, characterized in that: The cosmetics and skin care products include collagen moisturizing lotion, collagen cream and collagen facial mask.

9. The use according to claim 6, characterized in that: The food additive is added into bone and joint health food or anti-aging health food.

10. The use according to claim 6, characterized in that: The cosmetic medicine product includes a cosmetic medicine injection.